Ugly sell-off hits British Biotech By Mike Ward
Editor, Europe

OXFORD - Investors gave British Biotech (LSE:BBG; BBIOY) another hosing after it emerged that the company had suspended its director of clinical research, Andrew Millar, for alleged misconduct. When the dust settled at week's end, BBG's market value had been slashed by £128 million (US$209 million).